Malaria Clinical Trial
Official title:
Vanderbilt-Zambia Network for Innovation in Global Health Technology - Malaria mBEADS Diagnostics Development Cohort
The purpose of these studies is to evaluate the experimental approaches and device designs, in order to improve diagnostic performance of the RDT only. The results from the enhanced RDT methodology will be not be shared with patients or care providers, since they are as of yet, unproven.
Populations at risk for malaria infection need diagnostic technologies that are reliable and
sensitive in settings without electricity, clean water, or highly trained technicians. Macha
Research Trust and Zambia Ministry of Health are collaborating to identify and treat
low-level and asymptomatic malaria infections and evaluate elimination strategies. The
VZNIGHT research program will focus on development of technologies and approaches to
facilitate diagnosis and evaluation of asymptomatic malaria using high sensitivity, point of
care diagnostic technologies. The diagnostic technologies in development are now
sufficiently mature that a transition from laboratory-synthesized samples to primary human
specimens collected in the field is necessary to advance their development.
Specific Aim: The investigators will evaluate approaches using magnetic bead capture,
isolation, and surface tension valve transfer of biomarkers to improve the sensitivity of
already approved RDTs for detection of malaria infection. Results will be compared to those
obtained using unenhanced capillary blood specimens directly applied to approved malaria
RDTs (the current standard of care).
The purpose of these studies is to evaluate the experimental approaches and device designs
in a field setting, in order to improve diagnostic performance of the RDT only. Anonymous,
finger-prick blood specimens will be collected from individuals consenting to the study who
have been advised to undergo a malaria rapid diagnostic test as part of standard clinical
practice or public health surveillance. The results from the enhanced RDT methodology will
be not be shared with patients or care providers, since they are as of yet, unproven.
Results from rapid diagnostic tests that are approved for clinical use by international and
national governing bodies and that are administered at the same time as part of the typical
standard of care, will be shared with study participants by the administering clinician or
their representative in the clinical setting. Individuals who test positive for malaria
infection using standard RDT methods will receive standard of care treatment administered by
an authorized care provider.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
| Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
| Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
| Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
| Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
| Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
| Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
| Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
| Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
| Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
| Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
| Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
| Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
| Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
| Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
| Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
| Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
| Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
| Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
| Completed |
NCT02605720 -
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
|
Phase 3 |